PRIMO NUTRACEUTICALS INC. (CSE:PRMO) (OTC:BUGVF) (FSE:8BV) (DEU:8BV) (MUN:8BV) (STU:8BV) (“Primo” or the “Company”) is pleased to announce that it has satisfied the provisions of the information guidelines of National Policy 12-203, by filing its annual financial statements and MD&A for the year ended July 31, 2019, and therefore its cease trade order has been lifted and as of March 5, 2020 the Company is once again trading on the CSE under the symbol: PRMO.  The Company was not subject to any insolvency proceedings.

The Company also announces the appointment of Mr. Mark Bechtel as Corporate Secretary.


Mr. Bechtel is a securities lawyer with extensive experience in Canadian capital markets and exchanges. Presently Mr. Bechtel operates a law firm located in downtown Vancouver specializing in venture and emerging markets. As Corporate Secretary of Primo Mr. Bechtel will ensure that best practices for regulatory compliance are established and maintained.

The Company has also entered into a consulting agreement with Sheryl Dhillon to act as their Corporate Governance consultant.   Ms. Dhillon is a highly experienced corporate secretary with over fifteen years of experience.  She has extensive knowledge of corporate governance, as well as strong management skills and excellent corporate communications.  Ms. Dhillon acts as Corporate Secretary for several TSXV and CSE listed companies.

“The addition of Mr. Bechtel and Ms. Dhillon is a significant value-add to the Primo team.  Their cumulative experience in various disciplines will further empower the Company’s growth.  It is an exciting time for our Company.”  Comments from Mr. Andy Jagpal, CEO & President.

ON BEHALF OF THE BOARD OF DIRECTORS

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at:

Ph: 604-722-0305
Email: info@primoceuticals.com
http://primoceuticals.com/

www.thriveCBD.org

FORWARD LOOKING STATEMENTS:

This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

Click here to connect with Primo Nutraceuticals (CSE:PRMO) for an Investor Presentation.

Source

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less